Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2017 | 09-2017 | 06-2017 | 03-2017 | 12-2016 | |
| Operating Expenses | 14,493 | 7,881 | 8,967 | 7,799 | 0 |
| Operating Income | -14,493 | -7,881 | -8,967 | -7,799 | N/A |
| Interest Expense | 107 | 106 | 104 | 100 | 0 |
| Other Income | 12 | 13 | -181 | -181 | 0 |
| Pre-tax Income | -14,588 | -7,973 | -9,251 | -8,080 | 0 |
| Net Income Continuous | -14,588 | -7,973 | -9,251 | -8,080 | N/A |
| Net Income | $-14,588 | $-7,973 | $-9,251 | $-8,080 | $N/A |
| EPS Basic Total Ops | -22.56 | -12.24 | -15.22 | -13.98 | N/A |
| EPS Basic Continuous Ops | -22.68 | -12.25 | -15.22 | -13.97 | N/A |
| EPS Diluted Total Ops | -22.56 | -12.24 | -15.22 | -13.98 | N/A |
| EPS Diluted Continuous Ops | -22.68 | -12.25 | -15.22 | -13.97 | N/A |
| EBITDA(a) | $-14,437 | $-7,823 | $-8,912 | $-7,758 | $N/A |